Wrap Text
Dealings in securities by Life Healthcare, Directors, Prescribed Officers and the Company Secretary
LIFE HEALTHCARE GROUP HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
(Registration number: 2003/002733/06)
ISIN: ZAE000145892
JSE and A2X share code: LHC
("Life Healthcare" or "the Company")
LIFE HEALTHCARE FUNDING LIMITED
(Incorporated in the Republic of South Africa with limited liability)
(Registration number: 2016/273566/06)
LEI: 3789SJPQJZF8ZYXTZ394
Bond company code: LHFI
DEALINGS IN SECURITIES BY LIFE HEALTHCARE, DIRECTORS, PRESCRIBED OFFICERS,
DIRECTORS OF A MAJOR SUBSIDIARY AND THE COMPANY SECRETARY
In terms of the Listings Requirements of JSE Limited, Life Healthcare shareholders and noteholders
are hereby advised of the following dealings in securities under the rules of the Long-Term Incentive
Plan ("the LTIP") and the Single Incentive Plan ("SIP").
Name of entity: Life Healthcare
Nature of transaction: On market purchase of shares
Class of securities: Ordinary shares
Nature of interest: Direct beneficial
Clearance obtained: Yes
Date of transaction: 14 January 2025
Number of ordinary shares: 5,339,882
Volume weighted average price per share: R16.0548
Highest price per share: R16.4000
Lowest price per share: R15.9000
The total value of the transaction: R85,730,737.53
Date of transaction: 15 January 2025
Number of ordinary shares: 5,557,212
Volume weighted average price per share: R16.1820
Highest price per share: R16.3600
Lowest price per share: R15.8800
The total value of the transaction: R89,926,804.58
Date of transaction: 16 January 2025
Number of ordinary shares: 4,793,964
Volume weighted average price per share: R16.2058
Highest price per share: R16.3600
Lowest price per share: R15.8800
The total value of the transaction: R77,690,021.79
1. Long-Term Incentive Plan ("the LTIP")
Shareholders and noteholders are reminded that on 15 and 16 March 2022, the Executive Directors,
the Prescribed Officer, the Company Secretary and the Directors of the major subsidiaries of the
Company accepted rights to participate in the Company's Long-Term Incentive Plan (LTIP) – 2022
allocation.
The specified performance conditions related to this scheme have been met and vesting occurred on
31 December 2024.
The value of the vested performance shares in respect of the LTIP 2022 allocation was based on the
performance outcomes and the 30-day VWAP as at 31 December 2024. The after-tax value has been
utilised to purchase the shares. The number of LHC shares per participant was based on the average
3-day VWAP of 2,3 and 6 January 2025 of R16.6793 (allocation value), which would have been the
LHC share price had the Company been able to purchase the shares at that time.
A total of 5,835,437 of the purchased Life Healthcare shares have been acquired on market and will be
transferred to the trading account of the respective recipients, based on the proportionate value vesting.
The number of shares to be delivered to the personal trading account on an off-market basis for the
Executive Directors, the Prescribed Officer, the Company Secretary and the Directors of the major
subsidiaries of the Company, respectively, which will be held directly beneficial, is as follows:
Details of recipient Number of Life Total Allocation Value at LHC
Healthcare Shares share price of R16.6793
Peter Gerard Wharton-Hood – 460,116 R7,674,425.42
Director
Petrus Phillippus van der Westhuizen – 327,490 R5,462,312.94
Director
Adam Pyle – 227,393 R3,792,762.30
Prescribed Officer
Kurt Wylie – Director of a major 84,664 R1,412,138.58
subsidiary of the Company
Craig Koekemoer – Director of a major 97,907 R1,633,022.91
subsidiary of the Company
Joshila Ranchhod – 66,202 R1,104,204.83
Company Secretary
2. Single Incentive Plan ("the SIP")
As previously communicated to the market, the board of directors of the Company has approved the
introduction of the Single Incentive Plan, to incentivise and retain Eligible Employees. The first vesting
of the FY2024 allocation occurred on 26 November 2024. The participants were awarded restricted
Life Healthcare shares which will vest over the prescribed periods.
The calculation of the SIP was done by utilising the value of the deferral for each participant divided by
the Company's closing share price on 26 November 2024 of R17.66, after the Company's financial year
end results were announced. This would have been the purchase price per share had the Company
not been in a closed period. In terms of this the total number of shares to be allocated to the individuals
was 10,942,813.
A total of 9,855,621 Life Healthcare shares were acquired on market at an average price of R16.146
and a further 1,087,192 LHC shares was allocated from the shares held in trust from previously forfeited
shares.
Below are the restricted shares allocated on an off-market basis to each of the Executive Directors,
Prescribed Officer, Company Secretary and Directors of the major subsidiaries of the Company, which
will be held directly as a beneficial shareholding in accordance with the respective vesting
arrangements.
Details of recipient Vesting Period Total Number Allocation value
of Life based on the LHC
Healthcare share price of
Shares R17.66
Peter Wharton-Hood – Director One third vesting in 1,016,965 R17,959,601.90
each of years 3,4
and 5
Petrus Phillippus van der One third vesting in 670,724 R11,844,985.84
Westhuizen – Director each of years 3,4
and 5
Adam Mills Pyle – Prescribed One third vesting in 443,750 R7,836,625.00
Officer each of years 3,4
and 5
Joshila Ranchhod – Company One third vesting in R4,677,851.44
Secretary each of years 3,4 264,884
and 5
Kurt Aston Wylie – Director of a Full vesting after 3 158,770 R2,803,878.20
major subsidiary of the Company years
Craig Ian Koekemoer – Director of Full vesting after 3 179,037 R3,161,793.42
a major subsidiary of the years
Company
3. Matching Share Arrangement ("the MSA")
The vesting of the second tranche of the MSA occurred at the end of December 2024. The performance
conditions, in respect of these shares have been met. The Human Resources and Remuneration
Committee, via a majority, has approved the vesting. The closing price on date of Human Resources
and Remuneration Committee approval, i.e. 9 January 2025 was used as the vesting price, which is
R15.81 per share.
The following shares will be delivered to the trading accounts on an off-market basis to each of the
Directors and Prescribed Officer of the Company, which will be held directly beneficial as follows:
Details of Recipient Number of Life Total Value LHC shares
Healthcare attributable to sold to cover
Shares vesting Award tax liability
applying the
cumulative
average price
of the share
purchase of
R15.81
Peter Gerard Wharton-Hood – 287,568 R4,546,450 -
Director
Petrus Phillippus van der Westhuizen 116,866 R1,847,651 53,544
– Director
Adam Mills Pyle – 65,073 R1,028,804 29,283
Prescribed Officer
Petrus Phillippus van der Westhuizen (Chief Financial Officer) has sold a portion of shares that have
vested through the Company's MSA to settle the tax arising from the vesting:
Name of the Director: Petrus Phillippus van der Westhuizen
Nature of transaction: On market disposal of shares
Class of securities: Ordinary shares
Nature of interest: Direct beneficial
Clearance obtained: Yes
Date of transaction: 15 January 2025
Number of securities: 53,544
Disposal price per share: R16.00
Highest price per share: R16.1700
Lowest price per share: R16.1600
The total value of the transaction: R856,704
Adam Mills Pyle (Chief Growth and Strategy Officer) has sold a portion of shares that have vested
through the Company's MSA to settle the tax arising from the vesting:
Name of the Prescribed Officer: Adam Mills Pyle
Nature of transaction: On market disposal of shares
Class of securities: Ordinary shares
Nature of interest: Direct beneficial
Clearance obtained: Yes
Date of transaction: 15 January 2025
Number of securities: 29,283
Disposal price per share: R16.1646
Highest price per share: R16.1700
Lowest price per share: R16.1600
The total value of the transaction: R473,347.98
Clearance to deal has been obtained for all the transactions above in terms of the Listings Requirements
of the JSE.
Dunkeld
20 January 2025
Equity Sponsor
RAND MERCHANT BANK (A division of FirstRand Bank Limited)
Debt Sponsor
Questco – Corporate Advisory
Date: 20-01-2025 05:44:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
